To compare positron emission tomography (PET) measurements of fibrillar amyloid burden

Study identifier:D2750N00006

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II, Open Label, Non-Randomized Study of [18F]AZD4694 to Compare PET Measurements of Fibrillar Amyloid Burden Obtained Using Difference Scanning Parameters, Reference Region Procedures and to Assess Test-retest Reliability in Patients with AD & HV

Medical condition

Alzheimer’s disease

Phase

Phase 2

Healthy volunteers

Yes

Study drug

[18F]AZD4694

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 01 Feb 2010

Primary Completion Date: 01 Aug 2011

Study Completion Date: 01 Aug 2011

Study design

Allocation: Non-randomized
Endpoint Classification: N/A
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic

Verification:

Verified 01 Jan 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: A [18F]4694	Drug: [18F]AZD4694 [18F]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

[email protected]

Investigators

Principal Investigator

Eric M Reiman

Banner Alzheimer’s Institute